Biblio

Filters: Author is Inamoto, Yoshihiro [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Inamoto Y. [Adenovirus disease after hematopoietic cell transplantation]. Rinsho Ketsueki. 2023;64(9):1166-1175.

Metheny L, Callander NS, Hall AC, Zhang M-J, Bo-Subait K, Wang H-L, Agrawal V, A Al-Homsi S, Assal A, Bacher U, et al. Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults. Transplant Cell Ther. 2021.

Murthy GSubramania, Kim S, Estrada-Merly N, Abid MBilal, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, et al. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023.

Kawajiri A, Kitano S, Maeshima AMiyagi, Inamoto Y, Tajima K, Takemura T, Tanaka T, Ito A, Okinaka K, Kurosawa S, et al. Association of CD204 macrophages with poor outcomes of malignant lymphomas not in remission treated by allo-HCT. Eur J Haematol. 2019.

Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, et al. Association of Chronic Graft-versus-Host Disease with Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplant Cell Ther. 2022.

Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf D, Pidala J, Flowers MED, Arora M, Jagasia M, Arai S, et al. Association of organ severity with mortality and recurrent malignancy in chronic graft-versus-host disease. Haematologica. 2014.

Hashmi H, Kumar A, Kharfan-Dabaja MA, Munshi PN, Inamoto Y, DeFilipp ZM, Dholaria B, Jain T, Perales M-A, Carpenter PA, et al. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy. Transplant Cell Ther. 2024.

B

Bar M, Ott SM, E Lewiecki M, Sarafoglou K, Wu JY, Thompson MJ, Vaux JJ, Dean DR, Saag KG, Hashmi SK, et al. Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.

C

Inamoto Y. Calculate Your Risk of Heart Attack After Hematopoietic Cell Transplantation. JACC CardioOncol. 2023;5(4):518-519.

Sakai T, Uchida T, Iwama S, Sugisaki K, Yamada M, Inamoto Y, Oda T. A Case of Chronic Graft-versus-host Disease-associated Membranous Nephropathy Following Bone Marrow Transplantation, Successfully Treated with Rituximab. Intern Med. 2022.

Ito R, Inamoto Y, Inoue Y, Ito A, Tanaka T, Fuji S, Okinaka K, Kurosawa S, Kim S-W, Yamashita T, et al. Characterization of late acute and chronic graft-versus-host disease according to the 2014 NIH consensus criteria in Japanese patients. Biol Blood Marrow Transplant. 2018.

Arora M, Hemmer MT, Ahn KWoo, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RPeter, Inamoto Y, et al. CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.

Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, et al. Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.

Khera N, Majhail NS, Brazauskas R, Wang Z, He N, Aljurf MD, Akpek G, Atsuta Y, Beattie S, Bredeson CN, et al. Comparison of Characteristics and Outcomes of Trial Participants and Non-participants: Example of Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Biol Blood Marrow Transplant. 2015.

Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, et al. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016.

Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, et al. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.

Kurosawa S, Mori A, Tsukagoshi M, Onishi Y, Ohwada C, Mori T, Goto H, Asano-Mori Y, Nawa Y, Hino M, et al. Current status and needs of long-term follow-up clinics for hematopoietic cell transplant survivors: results of a nationwide survey in Japan. Biol Blood Marrow Transplant. 2020.

D

Deol A, Sengsayadeth S, Ahn KWoo, Wang H-L, Aljurf M, Antin JHarry, Battiwalla M, Bornhäuser M, Cahn J-Y, Camitta B, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016.

E

Akahoshi Y, Kimura S-I, Inamoto Y, Seo S, Muranushi H, Shimizu H, Ozawa Y, Tanaka M, Uchida N, Kanda Y, et al. Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2020.

Konuma T, Matsuda K, Shimomura Y, Tanoue S, Sugita J, Inamoto Y, Hirayama M, Ara T, Nakamae H, Ota S, et al. Effect of graft-versus-host disease on posttransplant outcomes following single cord blood transplantation in comparison to haploidentical transplantation with posttransplant cyclophosphamide for adult acute myeloid leukemia. Transplant Cell Ther. 2023.

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim S-W, Tanosaki R, Fukuda T. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016.

Yuda S, Fuji S, Onishi A, Tanaka T, Inamoto Y, Kurosawa S, Kim S-W, Fukuda T. Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.

F

Palmer J, Chai X, Martin PJ, Weisdorf D, Inamoto Y, Pidala J, Jagasia M, Pavletic S, Cutler C, Vogelsang G, et al. Failure-free Survival in a Prospective Cohort of Patients with Chronic Graft-Versus-Host Disease. Haematologica. 2015.

Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Ikeda M, Ueno T, Saito Y, Aihara Y, Matsuba Y, et al. Feasibility and usefulness of recommended screenings at long-term follow-up clinics for hematopoietic cell transplant survivors. Support Care Cancer. 2021.

H

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, DeAngelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, et al. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019.

Pages